AVF Research Session: Genetics, VTE Risk, and New Targets

Obesity, Genetics, and Chronic Venous Disease

Patients with obesity present with more severe venous symptoms but show greater relative improvement with conservative therapy, though compression is recommended less often. Genome-wide association studies confirm varicose vein disease is polygenic, implicating endothelial and inflammatory pathways as future drug targets, though documentation remains too inconsistent to link genotype to phenotype.

Superficial Thrombosis and Pediatric VTE Risk

Weight-adjusted intermediate-dose tinzaparin showed high efficacy and safety for superficial venous thrombosis with added risk factors such as age, obesity, or prior VTE. A pediatric cohort study found elevated BMI and central venous access were the strongest predictors of thrombosis, though risk models overlapped too much to guide prophylaxis.

Atypical Thrombosis and Emerging Anticoagulants

Behcet disease produces atypical thrombosis at unusual sites such as the vena cava and cerebral veins, managed with combined immunosuppression and anticoagulation. Rapid weight loss after bariatric surgery can narrow the aortomesenteric angle and cause Nutcracker syndrome, resolved surgically. Factor XI inhibitors are being studied to separate thrombosis prevention from bleeding risk.